Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

81.00 -2.08 (-2.50%)
Streaming Delayed Price Updated: 10:09 AM EST, Jan 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor
Via ACCESSWIRE
News headline image
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio? ↗
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72% 
Via Benzinga
News headline image
AT&T, Group 1 Automotive, Mattel, Seagate And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
Via ACCESSWIRE
News headline image
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
News headline image
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
Via ACCESSWIRE
News headline image
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
Via ACCESSWIRE
News headline image
3 Growth Stocks No One Is Watching (But They Should Be) ↗
While overlooked growth stocks present high risks, it’s difficult to find any other sector with as much upside potential. 
Via InvestorPlace
News headline image
Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600 ↗
Protagonist Therapeutics will join the SmallCap 600 on Wednesday. 
Via Investor's Business Daily
Topics Stocks
News headline image
Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control
Via ACCESSWIRE
News headline image
The 3 Best Biotech Stocks to Buy in June 2024 ↗
Explore the best biotech stocks to buy in June 2024, with insights on Protagonist, BridgeBio and Intellia. 
Via InvestorPlace
News headline image
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
Via ACCESSWIRE
News headline image
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
Via ACCESSWIRE
News headline image
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
News headline image
PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
Via ACCESSWIRE
News headline image
Turnstone Biologics Appoints William Waddill to its Board of Directors
From Turnstone Biologics Corp.
Via GlobeNewswire
News headline image
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
Via ACCESSWIRE
News headline image
Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
Via ACCESSWIRE
News headline image
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
Via ACCESSWIRE
News headline image
Protagonist Therapeutics Reports Granting of Inducement Awards
Via ACCESSWIRE
News headline image
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
Via ACCESSWIRE
News headline image
Why Is Japanese Drugmaker Takeda Stock Trading Lower Today? ↗
Takeda Pharmaceutical's Q3 2023 results: ¥235.9 billion core net profit, management changes, and a global collaboration deal for rusfertide. Fiscal year 2023 guidance reiterated. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
Via ACCESSWIRE
News headline image
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024
Via ACCESSWIRE
News headline image
Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Via ACCESSWIRE
News headline image
Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis
Via ACCESSWIRE
News headline image
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals
Via ACCESSWIRE
News headline image
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.